Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys

PLoS Pathogens

Volumn 3, Issue 1, 2007, Pages 0062-0066

  Oswald, Wendelien B ^a   Geisbert, Thomas W ^b   Davis, Kelly J ^b,d   Geisbert, Joan B ^b   Sullivan, Nancy J ^c   Jahrling, Peter B ^b,e   Parren, Paul W H I ^a,f   Burton, Dennis R ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d CHARLES RIVER LABORATORIES   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f GENMAB   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

KZ 52; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFECT; EBOLA VIRUS; HUMAN; IMMUNOHISTOCHEMISTRY; NONHUMAN; RHESUS MONKEY; TREATMENT FAILURE; VIREMIA; VIRUS INFECTION; VIRUS REPLICATION; ANIMAL; CLINICAL TRIAL; GUINEA PIG; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MACACA; PASSIVE IMMUNIZATION; SERODIAGNOSIS; VIRUS HEMORRHAGIC FEVER;

ANIMALIA; CAVIA; EBOLA VIRUS; MACACA; MACACA MULATTA;

ANIMALS; ANTIBODIES, MONOCLONAL; GUINEA PIGS; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNIZATION, PASSIVE; INJECTIONS, INTRAVENOUS; MACACA MULATTA; NEUTRALIZATION TESTS;

EID: 33846490649     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.0030009     Document Type: Article

References (30)

1. Casadevall A, Scharff MD (1995) Return to the past: The case for antibody-based therapies in infectious diseases. Clin Infect Dis 21: 150-161.
2. Parren PW, Burton DR (2001) The antiviral activity of antibodies in vitro and in vivo. Advan Immunol 77: 195-262.
3. Hangartner L, Zinkernagel RM, Hengartner H (2006) Antiviral antibody responses: The two extremes of a wide spectrum. Nat Rev Immunol 6: 231-243.
4. Guillaume V, Contamin H, Loth P, Grosjean I, Courbot MC, et al. (2006) Antibody prophylaxis and therapy against Nipah virus infection in hamsters. J Virol 80: 1972-1978.
5. Seiler P, Brundler MA, Zimmermann C, Weibel D, Bruns M, et al. (1998) Induction of protective cytotoxic T-cell responses in the presence of high titers of virus-neutralizing antibodies: Implications for passive and active immunization. J Exp Med 187: 649-654.
6. Parren PW, Geisbert TW, Maruyama T, Jahrling PB, Burton DR (2002) Pre- and post-exposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol 76: 6408-6412.
7. Burton DR (2002) Antibodies, viruses, and vaccines. Nat Rev Immunol 2: 706-713.
8. Sanchez A, Khan AS, Zaki SR, Nabel GJ, Ksiazek TG, et al. (2001) Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley PM, editors. Fields virology. Philadelphia: Lippincott, Williams, and Wilkins. pp. 1279-1304.
9. World Health Organization (2004) Ebola haemorrhagic fever. Geneva: World Health Organization. Available: http://www.who.int/mediacentre/factsheets/fs103/ en/. Accessed 21 December 2006.
10. Mupapa K, Massamba M, Kibadi K, Kuvula K, Bwaka A, et al. (1999) Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. J Infect Dis 179 (Suppl 1): S18-S23.
11. Maruyama T, Rodriguez LL, Jahrling PB, Sanchez A, Khan AS, et al. (1999) Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol 73: 6024-6030.
12. Jahrling PB, Geisbert J, Swearengen JR, Jaax GP, Lewis T, et al. (1996) Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch Virol 11: 135-140.
13. Jahrling PB, Geisbert TW, Geisbert JB, Swearengen JR, Bray M, et al. (1999) Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections. J Infect Dis 179 (Suppl 1): S224-S234.
14. Geisbert TW, Hensley LE, Geisbert JB, Jahrling PB (2002) Evidence against an important role for infectivity-enhancing antibodies in Ebola virus infections. Virology 293: 15-19.
15. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Larsen T, et al. (2003) Pathogenesis of Ebola hemorrhagic fever in primate models: Evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol 163: 2371-2382.
16. Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, et al. (2003) Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: A study in rhesus monkeys. Lancet 362: 1953-1958.
17. Borisevich IV, Mikhailov VV, Krasnianskii VP, Gradoboev VN, Lebedinskaia EV, et al. (1995) Development and study of the properties of immunoglobulin against Ebola fever. Vopr Virusol 40: 270-273.
18. Kudoyarova-Zubavichene NM, Sergeyev NN, Chepurnov AA, Netesov SV (1999) Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections. J Infect Dis 179 (Suppl 1): S218-S223.
19. Markin VA, Mikhailov VV, Krasnianskii VP, Borisevich IV, Firsova IV (1997) Developing principles for emergency prevention and treatment of Ebola fever. Vopr Virusol 42: 31-34.
20. Greenough TC, Babcock GJ, Roberts A, Hernandez HJ, Thomas WD Jr, et al. (2005) Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J Infect Dis 191: 507-514.
21. Connolly BM, Steele KE, Davis KJ, Geisbert TW, Kell WM, et al. (1999) Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis 179 (Suppl 1): S203-S217.
22. Ryabchikova EI, Kolesnikova LV, Luchko SV (1999) An analysis of features of pathogenesis in two animal models of Ebola virus infection. J Infect Dis 179 (Suppl 1): S199-S202.
23. Schnittler HJ, Feldmann H (1998) Marburg and Ebola hemorrhagic fevers: Does the primary course of infection depend on the accessibility of organ-specific macrophages? Clin Infect Dis 27: 404-406.
24. Schnittler HJ, Feldmann H (1999) Molecular pathogenesis of filovirus infections: Role of macrophages and endothelial cells. Curr Top Microbiol Immunol 235: 175-204.
25. Lekkerkerker AN, van Kooyk Y, Geijtenbeek TB (2006) Viral piracy: HIV-1 targets dendritic cells for transmission. Curr HIV Res 4: 169-176.
26. Jones SM, Feldmann H, Stroher U, Geisbert JB, Fernando L, et al. (2005) Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 11: 786-790.
27. Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, et al. (2003) Accelerated vaccination for Ebola virus haemorrhagic fever in nonhuman primates. Nature 424: 681-684.
28. National Research Council (1996) Guide for the care and use of laboratory animals. Washington (D. C.): Washington Academy Press. 125 p.
29. Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, et al. (2001) Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 75: 8340-8347.
30. Jahrling PB, Hesse RA, Eddy GA, Johnson KM, Callis RT, et al. (1980) Lassa virus infection of rhesus monkeys: Pathogenesis and treatment with ribavirin. J Infect Dis 141: 580-589.